Apollon Wealth Management LLC Grows Position in Teleflex Incorporated (NYSE:TFX)

Apollon Wealth Management LLC raised its position in shares of Teleflex Incorporated (NYSE:TFX) by 3.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,524 shares of the medical technology company’s stock after buying an additional 55 shares during the quarter. Apollon Wealth Management LLC’s holdings in Teleflex were worth $377,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of TFX. Janus Henderson Group PLC lifted its position in shares of Teleflex by 12.0% during the first quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after buying an additional 581,312 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Teleflex by 564.3% during the second quarter. Point72 Asset Management L.P. now owns 310,484 shares of the medical technology company’s stock valued at $65,304,000 after buying an additional 263,743 shares during the last quarter. Cooke & Bieler LP lifted its position in shares of Teleflex by 23.3% during the second quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock valued at $191,989,000 after buying an additional 172,335 shares during the last quarter. Ceredex Value Advisors LLC purchased a new stake in shares of Teleflex during the second quarter valued at about $25,550,000. Finally, National Bank of Canada FI lifted its position in shares of Teleflex by 1,008.2% during the second quarter. National Bank of Canada FI now owns 115,343 shares of the medical technology company’s stock valued at $24,388,000 after buying an additional 104,935 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Price Performance

Shares of NYSE:TFX opened at $192.15 on Monday. Teleflex Incorporated has a twelve month low of $189.95 and a twelve month high of $257.85. The company’s 50 day moving average is $230.35 and its 200 day moving average is $223.29. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The company has a market cap of $8.92 billion, a PE ratio of 38.20, a price-to-earnings-growth ratio of 1.97 and a beta of 1.18.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.11. The company had revenue of $764.40 million for the quarter, compared to the consensus estimate of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Teleflex’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.64 EPS. On average, sell-side analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be given a $0.34 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.71%. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Analyst Upgrades and Downgrades

Several research firms have commented on TFX. Royal Bank of Canada decreased their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Friday, November 1st. Mizuho cut their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Stephens upped their price objective on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $259.25.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.